Midwest BioResearch is not your ordinary
Contract Research Organization

MBR was started by former scientists, managers, and directors from major pharmaceutical companies to provide an outsourced solution for key areas of drug disposition and toxicology.  MBR’s staff has a deep understanding of the role that preclinical sciences play in the discovery and development of a successful drug candidate.

It is estimated that nearly 86 percent of drug failures are a result of either inadequate blood levels or unacceptable toxicity and side effects.  The ability to identify and understand both drug disposition and toxicology are key in compound selection and in the management of risk during development programs.

By focusing on specialized areas of drug disposition and toxicology, leveraging our pharmaceutical experience and external associations, and providing personalized proactive and responsive service, we aim to help you select and progress your protein or small molecule therapeutic out of discovery and through development faster and more efficiently.